drugset / Trial / NCT00895102
Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers
RandomizedCrossoverQuadruple-blind
Summary
The purpose of this study is to determine the bioavailability, pharmacokinetic and safety profiles of an experimental Hepatitis C virus (HCV) polymerase inhibitor in healthy volunteers.
Timeline
- Start
- 2009-04
- Primary completion
- 2009-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | dasabuvir | Small molecule | 400 mg | — |
| Comparator | dasabuvir | Small molecule | 1200 mg | — |
| Comparator | dasabuvir | Small molecule | 1600 mg | — |
| Comparator | dasabuvir | Small molecule | 2400 mg | — |